Joshua T. Pearson
Merck & Co., Inc., Rahway, NJ, USA (United States)(US)Amgen (United States)(US)
Publications by Year
Research Areas
Monoclonal and Polyclonal Antibodies Research, CAR-T cell therapy research, Lung Cancer Research Studies, Synthesis and Biological Evaluation, Chronic Lymphocytic Leukemia Research
Most-Cited Works
- → AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer(2020)224 cited
- → Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell–recruiting Antibody Optimized for Cytotoxicity and Cytokine Release(2019)123 cited
- → The kinetic mechanism for cytochrome P450 metabolism of Type II binding compounds: Evidence supporting direct reduction(2011)31 cited
- → Interleukin‐21 Receptor Blockade Inhibits Secondary Humoral Responses and Halts the Progression of Preestablished Disease in the (NZB × NZW)F1 Systemic Lupus Erythematosus Model(2015)29 cited
- → When I Cry Into My Icosahedral Mermaid Womb, The Sea Cradles Me: Creating Imaginary Water Worlds For Suicidal Depression and Healing Through Multisensory Environments(2022)1 cited
- → Supplementary Figure 6 from AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer(2023)
- → Supplementary Figures from Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell–recruiting Antibody Optimized for Cytotoxicity and Cytokine Release(2023)
- → Data from Targeting Multiple Myeloma with AMG 424, a Novel Anti-CD38/CD3 Bispecific T-cell–recruiting Antibody Optimized for Cytotoxicity and Cytokine Release(2023)
- → A Mixed and Mislabeled Bag(2021)